Home » Newsletters » BioWorld Science

BioWorld Science

April 28, 2009

View Archived Issues

Novel tools for post-transplant tacrolimus dose optimization reported

Banyu describes 4-sulfonylpiperidine derivatives for the treatment of diabetes

Kitasato Institute and Kyowa Hakko Kirin claim novel KB-3346-5 substances as antiinfective agents

Improved early virologic response rates seen with GI-5005 in phase II HCV study

Preclinical data on phase I antiangiogenic mAb, PF-03446962, presented

AEZS-126, a new orally bioavailable PI3K inhibitor shows preclinical antitumor activity

Intravitreal viral delivery of VEGF antagonist developed as therapy for ocular neovascularization

Intarcia completes enrollment in phase Ib clinical study of ITCA-650 in type 2 diabetes

Novel multitargeted kinase inhibitor displays potent antitumor activity in preclinical cancer models

Choongwae patents GSK-3beta inhibitors for the treatment of Alzheimer's disease

Novel PI3K inhibitors for cancer treatment jointly patented by Genentech and Roche

Antisense begins pivotal phase III trabedersen trial in aggressive brain tumors

Avila Therapeutics' novel agent AVL-181 silences HCV protease activity

Peregrine presents preliminary phase II bavituximab data in breast cancer

Pharmasset and Roche dose first patient in phase IIb clinical trial of HCV drug R-7128

CHMP recommends approval of pediatric formulation of Tracleer in PAH

Clinical study shows anti-HCV efficacy of NIM-811 with peginterferon

Janssen receives Japanese approval to market Risperdal Consta for schizophrenia

European Commission grants Wyeth marketing authorization for Conbriza

Novel Aurora kinase inhibitors claimed by Bayer for cancer treatment

FDA accepts for review Theravance's complete response for telavancin in cSSSI

FDA grants orphan drug designation to Pharming's Prodarsan for Cockayne syndrome

Phase III Nexavar trial in advanced melanoma does not meet primary endpoint

Phase II GSK-1838262 results reported for pain in diabetic peripheral neuropathy

Sepracor reports preliminary phase III Omnaris results in allergic rhinitis

Once-daily antiepileptic Zebinix approved in the European Union

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...